Literature DB >> 7408694

[Intravenous immunoglobulin administration for antibody deficiency (author's transl)].

T Luthardt.   

Abstract

Seven patients received a total of 23 infusions of a polyvalent largely monomeric and intravenously applicable immunoglobulin preparation (Sandoglobulin). Among them are two with congenital antibody deficiency syndrome. One of them, who has agammaglobulinaemia type Bruton, is still receiving 9 g Sandoglobulin every three months. During the now 40-week period of observation the IgG serum level has remained adequately high, and the patient has had no infection; half-life of the Sandoglobulin is 32.4 days. In the other patient, with recently diagnosed hyper-IgM syndrome, 6 g Sandoglobulin were administered every month or every second month. During an observation period of 44 weeks he had not further infections. The initially much increased IgM serum level (16 g/l) slowly but definitely fell during substitution to 9 g/l at the end of the observation; half-life of Sandoglobulin is 34.1 days. All 23 Sandoglobulin infusions were given without side-effects.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7408694     DOI: 10.1055/s-2008-1070798

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  2 in total

Review 1.  Basic principles of intravenous immunoglobulin (IVIg) treatment.

Authors:  Martin Stangel; Refik Pul
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

2.  [Tolerance of a new intravenously applied immunoglobulin preparation and its effect on serum globulin levels].

Authors:  W Hansi; H Heimpel; S Barandun; O Lutz
Journal:  Infection       Date:  1982 Nov-Dec       Impact factor: 3.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.